Capital World Investors trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 59.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,045,288 shares of the company's stock after selling 5,963,626 shares during the period. Capital World Investors owned about 0.21% of Kenvue worth $86,367,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Grove Bank & Trust lifted its stake in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue in the 4th quarter valued at approximately $29,000. SRS Capital Advisors Inc. raised its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC grew its holdings in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Price Performance
Shares of KVUE stock traded up $0.28 during midday trading on Friday, reaching $23.03. 22,249,585 shares of the company were exchanged, compared to its average volume of 17,101,629. The company's 50 day moving average price is $23.01 and its two-hundred day moving average price is $22.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market cap of $44.19 billion, a P/E ratio of 43.45, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's payout ratio is currently 154.72%.
Analyst Ratings Changes
A number of research analysts have commented on KVUE shares. Barclays reduced their target price on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a report on Monday, April 14th. Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective on the stock. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Canaccord Genuity Group raised their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Citigroup boosted their price objective on shares of Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Kenvue has an average rating of "Hold" and an average price target of $24.42.
Read Our Latest Research Report on KVUE
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
